Generate Biomedicines vs Elevance Health

Side-by-side comparison of AI visibility scores, market position, and capabilities

Elevance Health leads in AI visibility (92 vs 57)
Generate Biomedicines logo

Generate Biomedicines

ChallengerHealthcare Tech

AI Drug Discovery & Generative Biology

Generative biology biotech using AI to design protein therapeutics. IPO'd on Nasdaq (GENB) Feb 2026, raising $400M. Lead drug GB-0895 in Phase 3 for severe asthma.

AI VisibilityBeta
Overall Score
C57
Category Rank
#1 of 1
AI Consensus
56%
Trend
up
Per Platform
ChatGPT
63
Perplexity
56
Gemini
50

About

Generate Biomedicines is a clinical-stage biotech founded in 2018 by Flagship Pioneering, headquartered in Somerville, Massachusetts. The company pioneers generative biology, using ML and large-scale experimental systems to design protein therapeutics. Its platform combines diffusion and graph-based AI models with high-throughput biohardware. The pipeline spans immunology, oncology, and infectious diseases.

Full profile
Elevance Health logo

Elevance Health

LeaderHealthcare Tech

Enterprise

Indianapolis BCBS managed care (NYSE: ELV) ~$175B FY2024 revenue; Anthem renamed 2022, BCBS exclusive in 14 states, Carelon health services, Medicaid/MA medical cost pressure competing with UnitedHealth and Cigna.

AI VisibilityBeta
Overall Score
A92
Category Rank
#194 of 290
AI Consensus
68%
Trend
down
Per Platform
ChatGPT
88
Perplexity
88
Gemini
88

About

Elevance Health, Inc. (formerly Anthem, Inc.) is an Indianapolis, Indiana-based managed care and health services company — publicly traded on the New York Stock Exchange (NYSE: ELV) as an S&P 500 Health Care component — providing health insurance plans under the Blue Cross Blue Shield brand in 14 states (Indiana, Georgia, California, Colorado, Connecticut, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, Wisconsin), Medicare Advantage, Medicaid managed care, and commercial employer-sponsored health plans through Carelon (pharmacy and behavioral health services — formerly IngenioRx) to approximately 47 million medical members through approximately 100,000 employees. In fiscal year 2024, Elevance Health reported revenues of approximately $175 billion (predominantly premium revenues from employer-sponsored and government-program health plan members), with operating income under pressure from medical cost increases in the Medicaid segment (post-COVID health utilization normalization causing medical costs to exceed Medicaid actuarial pricing expectations set during the pandemic period of reduced care utilization). CEO Gail Boudreaux has executed the company's transformation from Anthem to Elevance Health (rebranded June 2022) — reflecting the broadened value proposition beyond health insurance into health services: Carelon Services (behavioral health, pharmacy benefit management, utilization management, home health services for both Elevance and external health plan clients) represents the strategy of building a health services ecosystem that retains value within the Elevance enterprise rather than paying external PBMs, behavioral health managers, and care management vendors.

Full profile

AI Visibility Head-to-Head

57
Overall Score
92
#1
Category Rank
#194
56
AI Consensus
68
up
Trend
down
63
ChatGPT
88
56
Perplexity
88
50
Gemini
88
68
Claude
86
65
Grok
99

Key Details

Category
AI Drug Discovery & Generative Biology
Enterprise
Tier
Challenger
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Generate Biomedicines
AI Drug Discovery & Generative Biology

Integrations

Only Elevance Health
Generate Biomedicines is classified as company. Elevance Health is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.